ACIU News

class="">Eight companies went public in the year’s most active week. Three priced above the range and each finished above its IPO price (average return of 38%). Biotech Novan and ad-tech platform The Trade Desk led the group with a 67% and 65% first day pop, respectively. After disinterest earlier in the year, the IPO market is finally showing signs of strong initial deman...read more

AC Immune, a Swiss biotech developing therapies for Alzheimer's, partnered with Genentech, raised $66 million by offering 6 million shares at $11, the low end of the range of $11 to $13. AC Immune plans to list on the Nasdaq under the symbol ACIU. Credit Suisse, Jefferies and Leerink Partners acted as lead managers on the deal....read more

Nine deals are on the IPO calendar for the week ahead, aiming to raise a combined $1.2 billion. Set to be the most active week of 2016, the wave of deals counts three founder-led high-growth software companies and a telecom equipment provider. Other deals include two consumer brands, two biotechs and one bank.

AC Immune, which is a Swiss biotech developing therapies for Alzheimer's disease, announced terms for its IPO on Tuesday. The Lausanne, Switzerland-based company plans to raise $55 million by offering 4.5 million shares at a price range of $11 to $13. Insiders intend to purchase $30 million worth of shares in the offering. At the midpoint of the proposed range, AC Immune would...read more